<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(4)</volume><submitter>Mostafa AMA</submitter><pubmed_abstract>This study highlights the use of &lt;sup>89&lt;/sup>Zr-oxalate in diagnostic applications with the help of WinAct and IDAC2.1 software. It presents the biodistribution of the drug in various organs and tissues, including bone, blood, muscle, liver, lung, spleen, kidneys, inflammations, and tumors, and analyzes the maximum amount of nuclear transformation per Bq intake for each organ. The retention time of the maximum nuclear transformation and the absorbed doses of the drug in various organs and tissues are also examined. Data from clinical and laboratory studies on radiopharmaceuticals are used to estimate the coefficients of transition. The accumulation and excretion of the radiopharmaceutical in the organs is assumed to follow an exponential law. The coefficients of transition from the organs</pubmed_abstract><journal>Biomedicines</journal><pagination>1173</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10135474</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation.</pubmed_title><pmcid>PMC10135474</pmcid><pubmed_authors>Issa SAM</pubmed_authors><pubmed_authors>Zhukovsky MV</pubmed_authors><pubmed_authors>Zakaly HMH</pubmed_authors><pubmed_authors>Mostafa AMA</pubmed_authors><pubmed_authors>Alrowaili ZA</pubmed_authors><pubmed_authors>Uosif MAM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation.</name><description>This study highlights the use of &lt;sup>89&lt;/sup>Zr-oxalate in diagnostic applications with the help of WinAct and IDAC2.1 software. It presents the biodistribution of the drug in various organs and tissues, including bone, blood, muscle, liver, lung, spleen, kidneys, inflammations, and tumors, and analyzes the maximum amount of nuclear transformation per Bq intake for each organ. The retention time of the maximum nuclear transformation and the absorbed doses of the drug in various organs and tissues are also examined. Data from clinical and laboratory studies on radiopharmaceuticals are used to estimate the coefficients of transition. The accumulation and excretion of the radiopharmaceutical in the organs is assumed to follow an exponential law. The coefficients of transition from the organs</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-22T05:14:38.494Z</modification><creation>2025-04-05T21:18:34.072Z</creation></dates><accession>S-EPMC10135474</accession><cross_references><pubmed>37189792</pubmed><doi>10.3390/biomedicines11041173</doi></cross_references></HashMap>